TN2014000360A1 - Cx3cr1-binding polypeptides - Google Patents

Cx3cr1-binding polypeptides

Info

Publication number: TN2014000360A1
Authority: TN; Tunisia
Prior art keywords: polypeptides; cx3cr1; binding polypeptides; compositions; relates
Prior art date: 2012-02-27

Application number

TNP2014000360A

Other languages

English (en)

Inventor

Sanjaya Singh

Alisa K Waterman

Erik Depla

Toon Laeremans

Hoorick Diane Van

Cedric Jozef Neotere Ververken

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-27

Filing date

2014-08-26

Publication date

2015-12-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000360(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-26 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-12-21 Publication of TN2014000360A1 publication Critical patent/TN2014000360A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)

TNP2014000360A 2012-02-27 2014-08-26 Cx3cr1-binding polypeptides TN2014000360A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261603622P	2012-02-27	2012-02-27
PCT/US2013/027580 WO2013130381A1 (fr)	2012-02-27	2013-02-25	Polypeptides se liant au cx3cr1

Publications (1)

Publication Number	Publication Date
TN2014000360A1 true TN2014000360A1 (en)	2015-12-21

Family

ID=47884535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2014000360A TN2014000360A1 (en)	2012-02-27	2014-08-26	Cx3cr1-binding polypeptides

Country Status (27)

Country	Link
US (6)	US9035029B2 (fr)
EP (2)	EP4050027A3 (fr)
JP (1)	JP6101715B2 (fr)
KR (1)	KR102008136B1 (fr)
CN (3)	CN108610421B (fr)
AP (1)	AP2014007791A0 (fr)
AR (1)	AR090158A1 (fr)
AU (1)	AU2013226340B2 (fr)
CA (1)	CA2862182A1 (fr)
CL (1)	CL2014002072A1 (fr)
EA (1)	EA028183B1 (fr)
EC (1)	ECSP14020402A (fr)
GE (1)	GEP201706773B (fr)
IL (3)	IL291571B2 (fr)
IN (1)	IN2014DN05756A (fr)
MD (1)	MD4548C1 (fr)
MX (1)	MX349192B (fr)
NZ (1)	NZ627260A (fr)
PE (1)	PE20141859A1 (fr)
PH (2)	PH12021553014A1 (fr)
SG (1)	SG11201405283SA (fr)
TN (1)	TN2014000360A1 (fr)
TW (1)	TWI598361B (fr)
UA (1)	UA115781C2 (fr)
UY (1)	UY34644A (fr)
WO (1)	WO2013130381A1 (fr)
ZA (3)	ZA201405021B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9101674B2 (en)	2010-03-29	2015-08-11	Vib Vzw	Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en)	2010-03-29	2017-01-31	Vib Vzw	Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
MX349192B (es)	2012-02-27	2017-07-18	Boehringer Ingelheim Int	Polipeptidos de union a cx3cr1.
JP2016534114A (ja) *	2013-08-21	2016-11-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｘ３ｃｒ１標的化イメージング剤並びに疾病の診断及び処置におけるその使用
RU2609627C2 (ru) *	2014-09-26	2017-02-02	Закрытое Акционерное Общество "Биокад"	Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
JP6913682B2 (ja) *	2015-07-23	2021-08-04	インヒブリックス，インコーポレイテッド	多価および多重特異性ｇｉｔｒ結合融合タンパク質
CA3009075A1 (fr) *	2016-01-11	2017-07-20	Inhibrx, Inc.	Proteines de fusion multivalentes et multispecifiques fixant ox40
EP3426689A4 (fr) *	2016-03-08	2020-01-15	Maverick Therapeutics, Inc.	Protéines de liaison inductibles et méthodes d'utilisation
US12128102B2 (en)	2016-03-08	2024-10-29	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
ES3041302T3 (en)	2016-11-29	2025-11-11	Nat Center Neurology & Psychiatry	Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases
US20190367623A1 (en) *	2017-01-17	2019-12-05	Yeda Research And Development Co. Ltd.	Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
IL302614B2 (en)	2017-09-08	2025-04-01	Maverick Therapeutics Inc	Binding proteins are activated under limited conditions
KR20210044243A (ko)	2018-08-13	2021-04-22	인히브릭스, 인크.	Ox40 결합 폴리펩티드 및 이의 용도
CN114390938B (zh)	2019-03-05	2025-03-21	武田药品工业有限公司	受约束的条件性活化的结合蛋白
CN110675421B (zh) *	2019-08-30	2022-03-15	电子科技大学	基于少量标注框的深度图像协同分割方法
US20240109954A1 (en) *	2021-02-01	2024-04-04	The General Hospital Corporation	Fc-enhanced antibodies for prevention and treatment of ebola virus infection
TW202246334A (zh) *	2021-02-02	2022-12-01	美商美國禮來大藥廠	Gitr拮抗劑及其使用方法
KR20250040019A (ko)	2022-07-18	2025-03-21	아블린쓰	Cx3cr1 결합 화합물, 이의 용도, 및 관련 방법
EP4640709A1 (fr)	2022-12-22	2025-10-29	Chiome Bioscience Inc.	Anticorps anti-cx3cr1 humain
WO2025149667A1 (fr)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Conjugués anticorps-médicament et leurs utilisations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2325541T3 (es)	1992-08-21	2009-09-08	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
EP0739981A1 (fr)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
WO2001060406A1 (fr) *	2000-02-18	2001-08-23	Millennium Pharmaceuticals, Inc.	Methodes therapeutiques ciblant la fractalkine ou cx3cr1
JP2003530839A (ja)	2000-04-12	2003-10-21	プリンシピアファーマスーティカルコーポレイション	アルブミン融合タンパク質
US20020192212A1 (en) *	2001-03-19	2002-12-19	Toshio Imai	Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
JP4303105B2 (ja)	2001-06-28	2009-07-29	ドマンティスリミテッド	二重特異性リガンドとその利用
JP4123856B2 (ja)	2001-07-31	2008-07-23	日油株式会社	生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
US20050069962A1 (en)	2001-10-12	2005-03-31	Archer Robert M	Antibody complexes and methods for immunolabeling
CA2484556A1 (fr)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
US20060160076A1 (en)	2002-06-10	2006-07-20	Meatabolex, Inc.	Methods of treating and diagnosing diabetes with cx3cr1 modulators
EP1558647B1 (fr)	2002-11-08	2015-06-10	Ablynx N.V.	Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
AU2003300133B2 (en)	2002-12-31	2008-11-13	Nektar Therapeutics	Hydrolytically stable maleimide-terminated polymers
PL1639011T3 (pl)	2003-06-30	2009-05-29	Domantis Ltd	Pegilowane przeciwciała jednodomenowe (dAb)
WO2005103684A2 (fr)	2004-04-20	2005-11-03	Bayer Healthcare Ag	Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
KR20070084170A (ko)	2004-10-13	2007-08-24	아블린쓰 엔.브이.	알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
EP1806145B1 (fr)	2004-10-29	2017-08-16	Eisai R&D Management Co., Ltd.	Médicament contre les maladies inflammatoires
HUE045710T2 (hu)	2005-05-18	2020-01-28	Ablynx Nv	Javított, alfa tumor nekrózis faktor elleni nanobodies
AU2006278260B2 (en)	2005-08-08	2012-03-08	Onconon, Llc.	Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
CN101370525B (zh) *	2005-08-19	2013-09-18	Abbvie公司	双重可变结构域免疫球蛋白及其用途
CA2666599A1 (fr)	2006-08-18	2008-02-21	Ablynx N.V.	Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
CA2663042A1 (fr) *	2006-09-08	2008-03-13	Ablynx N.V.	Proteines a demi-vie longue se liant a l'albumine serique
CN101611056A (zh)	2006-12-05	2009-12-23	埃博灵克斯股份有限公司	能够结合于血清蛋白的肽
DE112009000507T5 (de)	2008-03-05	2011-02-10	Ablynx Nv	Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2009127691A1 (fr)	2008-04-17	2009-10-22	Ablynx N.V.	Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
DK2285408T3 (en)	2008-06-05	2019-02-04	Ablynx Nv	AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
WO2010070394A1 (fr)	2008-12-17	2010-06-24	Universite Pierre Et Marie Curie-Paris Vi	Modulateurs du récepteur cx3cr1 et leurs utilisations thérapeutiques
EP2486056A1 (fr) *	2009-10-09	2012-08-15	Ablynx N.V.	Domaine variable unique immunoglobulinique dirigé contre cxcr4 humain et autres protéines associées à des cellules, et procédés d'obtention
WO2011044377A2 (fr)	2009-10-09	2011-04-14	Cell Point, Llc	Conjugués chélate-ligand de ciblage pour l'imagerie cardiovasculaire
WO2012078633A2 (fr) *	2010-12-07	2012-06-14	Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene	Méthodes d'inhibition de la métastase d'un cancer
MX349192B (es)	2012-02-27	2017-07-18	Boehringer Ingelheim Int	Polipeptidos de union a cx3cr1.
JP2016534114A (ja)	2013-08-21	2016-11-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｘ３ｃｒ１標的化イメージング剤並びに疾病の診断及び処置におけるその使用

2013
- 2013-02-25 MX MX2014009864A patent/MX349192B/es active IP Right Grant
- 2013-02-25 IN IN5756DEN2014 patent/IN2014DN05756A/en unknown
- 2013-02-25 WO PCT/US2013/027580 patent/WO2013130381A1/fr not_active Ceased
- 2013-02-25 GE GEAP201313583A patent/GEP201706773B/en unknown
- 2013-02-25 SG SG11201405283SA patent/SG11201405283SA/en unknown
- 2013-02-25 PE PE2014001293A patent/PE20141859A1/es active IP Right Grant
- 2013-02-25 CN CN201810147778.3A patent/CN108610421B/zh active Active
- 2013-02-25 CA CA2862182A patent/CA2862182A1/fr not_active Abandoned
- 2013-02-25 PH PH1/2021/553014A patent/PH12021553014A1/en unknown
- 2013-02-25 KR KR1020147023938A patent/KR102008136B1/ko active Active
- 2013-02-25 AU AU2013226340A patent/AU2013226340B2/en active Active
- 2013-02-25 IL IL291571A patent/IL291571B2/en unknown
- 2013-02-25 CN CN202210946091.2A patent/CN115925938A/zh active Pending
- 2013-02-25 JP JP2014558920A patent/JP6101715B2/ja active Active
- 2013-02-25 UA UAA201410430A patent/UA115781C2/uk unknown
- 2013-02-25 EP EP22168124.0A patent/EP4050027A3/fr active Pending
- 2013-02-25 AP AP2014007791A patent/AP2014007791A0/xx unknown
- 2013-02-25 PH PH1/2014/501912A patent/PH12014501912B1/en unknown
- 2013-02-25 EP EP13709641.8A patent/EP2820046B1/fr active Active
- 2013-02-25 MD MDA20140104A patent/MD4548C1/ro not_active IP Right Cessation
- 2013-02-25 CN CN201380016996.9A patent/CN104245735B/zh active Active
- 2013-02-25 EA EA201400964A patent/EA028183B1/ru not_active IP Right Cessation
- 2013-02-25 US US13/775,307 patent/US9035029B2/en active Active
- 2013-02-25 NZ NZ627260A patent/NZ627260A/en unknown
- 2013-02-25 IL IL311502A patent/IL311502A/en unknown
- 2013-02-26 TW TW102106771A patent/TWI598361B/zh active
- 2013-02-26 AR ARP130100585A patent/AR090158A1/es active IP Right Grant
- 2013-02-27 UY UY0001034644A patent/UY34644A/es unknown
2014
- 2014-07-09 ZA ZA2014/05021A patent/ZA201405021B/en unknown
- 2014-08-05 CL CL2014002072A patent/CL2014002072A1/es unknown
- 2014-08-07 IL IL234018A patent/IL234018B2/en unknown
- 2014-08-26 TN TNP2014000360A patent/TN2014000360A1/fr unknown
- 2014-09-25 EC ECIEPI201420402A patent/ECSP14020402A/es unknown
2015
- 2015-04-09 US US14/682,131 patent/US9458235B2/en active Active
2016
- 2016-08-22 US US15/242,639 patent/US9783612B2/en active Active
2017
- 2017-09-29 US US15/720,792 patent/US10385134B2/en active Active
2019
- 2019-07-09 US US16/505,773 patent/US11384151B2/en active Active
2022
- 2022-06-09 US US17/836,473 patent/US12221487B2/en active Active
2023
- 2023-09-19 ZA ZA2023/08846A patent/ZA202308846B/en unknown
- 2023-09-19 ZA ZA2023/08845A patent/ZA202308845B/en unknown

Also Published As

Publication number	Publication date
EP2820046A1 (fr)	2015-01-07
EA028183B1 (ru)	2017-10-31
WO2013130381A1 (fr)	2013-09-06
US20130224224A1 (en)	2013-08-29
US20180030141A1 (en)	2018-02-01
BR112014021080A2 (pt)	2017-07-04
US20240279349A2 (en)	2024-08-22
HK1205154A1 (en)	2015-12-11
IL234018B1 (en)	2023-01-01
PH12014501912B1 (en)	2023-01-18
AR090158A1 (es)	2014-10-22
AP2014007791A0 (en)	2014-07-31
US10385134B2 (en)	2019-08-20
ECSP14020402A (es)	2015-11-30
MD4548B1 (ro)	2018-01-31
IL291571B2 (en)	2024-08-01
US20240026013A2 (en)	2024-01-25
PH12014501912A1 (en)	2014-11-24
ZA202308845B (en)	2025-03-26
US20160355595A1 (en)	2016-12-08
EP2820046B1 (fr)	2022-06-15
CA2862182A1 (fr)	2013-09-06
US9458235B2 (en)	2016-10-04
UY34644A (es)	2013-09-02
SG11201405283SA (en)	2014-10-30
US9783612B2 (en)	2017-10-10
TWI598361B (zh)	2017-09-11
JP2015509368A (ja)	2015-03-30
KR20140130685A (ko)	2014-11-11
CL2014002072A1 (es)	2015-01-23
US20190322753A1 (en)	2019-10-24
JP6101715B2 (ja)	2017-03-22
NZ627260A (en)	2015-10-30
AU2013226340B2 (en)	2017-06-22
IL291571B1 (en)	2024-04-01
IL234018A0 (en)	2014-09-30
US11384151B2 (en)	2022-07-12
PE20141859A1 (es)	2014-12-17
EP4050027A3 (fr)	2022-11-30
IN2014DN05756A (fr)	2015-04-10
US20150239971A1 (en)	2015-08-27
IL311502A (en)	2024-05-01
GEP201706773B (en)	2017-11-27
MX2014009864A (es)	2014-10-24
MX349192B (es)	2017-07-18
CN108610421B (zh)	2022-08-19
US20230046772A1 (en)	2023-02-16
PH12021553014A1 (en)	2022-09-05
US9035029B2 (en)	2015-05-19
CN104245735A (zh)	2014-12-24
CN104245735B (zh)	2018-02-23
CN115925938A (zh)	2023-04-07
TW201348256A (zh)	2013-12-01
IL234018B2 (en)	2023-05-01
EA201400964A1 (ru)	2015-02-27
KR102008136B1 (ko)	2019-08-08
US12221487B2 (en)	2025-02-11
UA115781C2 (uk)	2017-12-26
ZA201405021B (en)	2024-09-25
MD4548C1 (ro)	2018-08-31
CN108610421A (zh)	2018-10-02
MD20140104A2 (ro)	2015-02-28
EP4050027A2 (fr)	2022-08-31
IL291571A (en)	2022-05-01
ZA202308846B (en)	2025-03-26
AU2013226340A1 (en)	2014-07-31

Publication	Publication Date	Title
ZA202308845B (en)	2025-03-26	Cx3cr1-binding polypeptides
SA518400424B1 (ar)	2022-08-17	جزيئات الجسم المضاد لعلاج السرطان
MX2015008446A (es)	2016-10-26	Composiciones de proteinas de union multivalentes.
MY177065A (en)	2020-09-03	4-1bb binding molecules
MX351565B (es)	2017-10-19	Colageno 7 y metodos relacionados.
HK1258509A1 (zh)	2019-11-15	Gitr激动剂
NZ702457A (en)	2016-09-30	Anti-fcrn antibodies
PH12014502179B1 (en)	2014-12-10	Ang2-binding molecules
PH12016500275B1 (en)	2019-11-29	Antibodies
WO2014076321A8 (fr)	2014-09-18	Nouveaux polypeptides de liaison spécifique et leurs utilisations
PH12014501970A1 (en)	2014-11-17	Antibodies to bradykinin b1 receptor ligands
IN2014MN01562A (fr)	2015-05-08
MX366178B (es)	2019-07-01	Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
IN2013MN01394A (fr)	2015-06-12
WO2011085134A3 (fr)	2011-10-20	Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
MX2015012281A (es)	2015-12-16	Proteinas de union a tnf mejoradas.
MX2015014198A (es)	2015-12-11	Anticuerpos cuyo objetivo es m-csf.
TN2014000395A1 (en)	2015-12-21	Antibodies to bradykinin b1 receptor ligands